USD
$0.00
(0.00%
)At Close (As of Sep 9, 2025)
$3.07M
Market Cap
-
P/E Ratio
-3.98
EPS
$4.09
52 Week High
$0.66
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$14M |
Selling General And Administrative | $8.6M |
Research And Development | $5.8M |
Operating Expenses | $14M |
Investment Income Net | - |
Net Interest Income | $402K |
Interest Income | $402K |
Interest Expense | $0 |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $14M |
Income Before Tax | -$13M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$13M |
Comprehensive Income Net Of Tax | - |
Ebit | -$28M |
Ebitda | -$13M |
Net Income | -$13M |
Field | Value (USD) |
---|---|
Total Assets | $4.2M |
Total Current Assets | $4.2M |
Cash And Cash Equivalents At Carrying Value | $4M |
Cash And Short Term Investments | $4M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $0 |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $0 |
Other Current Assets | $281K |
Other Non Current Assets | - |
Total Liabilities | $5.9M |
Total Current Liabilities | $5.9M |
Current Accounts Payable | $3.9M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $0 |
Capital Lease Obligations | $0 |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $2M |
Other Non Current Liabilities | - |
Total Shareholder Equity | -$1.7M |
Treasury Stock | - |
Retained Earnings | -$695M |
Common Stock | $2K |
Common Stock Shares Outstanding | $1.9M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$13M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | - |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $13M |
Cashflow From Financing | $3M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$13M |
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$14M |
Selling General And Administrative | $8.6M |
Research And Development | $5.8M |
Operating Expenses | $14M |
Investment Income Net | - |
Net Interest Income | $402K |
Interest Income | $402K |
Interest Expense | $0 |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $14M |
Income Before Tax | -$13M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$13M |
Comprehensive Income Net Of Tax | - |
Ebit | -$28M |
Ebitda | -$13M |
Net Income | -$13M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.